Prescribing direct-acting oral anticoagulants - mind the evidence gap

Elizabeth Adeyere, Carmela Maniero, Emma Magavern, Robin Ferner, Patricia McGettigan

Research output: Contribution to journalArticlepeer-review

Abstract

Direct-acting oral anticoagulants (DOACs) are licensed for the prevention of thromboembolism in non-valvular atrial fibrillation, amongst other indications. Prescribers use information derived from the summary of product characteristics which is based on the key trials supporting the DOAC's market authorisation. However, prescribers may not be aware of the limitations within these trials regarding underrepresentation of patient populations commonly encountered in clinical practice and how this may adversely impact them. This review highlights the gaps in the licensing evidence using four clinical vignettes that explore prescribing challenges in older adults, female patients, patients with obesity and patients from non-Europid ethnic backgrounds.
Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
Early online date30 Jun 2022
DOIs
Publication statusE-pub ahead of print - 30 Jun 2022

Keywords

  • anticoagularnts
  • cardiovascular pharmacology
  • drug information
  • drug regulation
  • medication safety

Fingerprint

Dive into the research topics of 'Prescribing direct-acting oral anticoagulants - mind the evidence gap'. Together they form a unique fingerprint.

Cite this